Search results

Gill/Hyde Group - BBSRC/AViP Studentships - Using Directed Evolution to Improve Lentiviral Vector Targeting

Gill/Hyde Group - BBSRC/AViP Studentships - Improved viral vector design for homology-independent targeted integration (HITI)

MRC Enterprise Studentship - Inter-vendor standardisation and quality assurance of quantitative cardiovascular magnetic resonance (CMR) T1-mapping for clinical practice and trials

MRC Enterprise Studentship - Determining the relevance of metabolic pathways as a therapeutic target in non-alcoholic fatty liver disease (NAFLD) cirrhosis

MRC Enterprise Studentship - Non-invasive phenotyping of muscle function using multi-nuclear MR

Rorsman Group - Preferential Gq signalling in diabetes: an electrical switch in incretin action and in diabetes progression?

Toepfer Group - Elucidating the role of disease modifying gene variants in inherited cardiomyopathies using induced pluripotent stem cell derived cardiomyocytes and CRISPR/Cas-9.

David Hodson Group - Understanding how glucagon-like peptide-1 (GLP1) and gastric inhibitory polypeptide (GIP) receptors contribute to metabolism in complex tissues

Curry Group - The coagulopathy of major haemorrhage: how does the aetiology of major bleeding affect the coagulation changes and how can haematological markers be best used to stratify risks of bleeding and need for transfusion therapy?

Wilkinson Group - From basic biology to novel translational applications of haematopoietic stem cells

Valkovič Group - Non-invasive cardiac metabolism assessment using ultra-high field (7T) MR Spectroscopy

Chakraverty Group - Immunotherapy

Our group is interested in developing novel immunotherapeutic approaches for leukaemia. Clinical approaches currently used include allogeneic haematopoietic stem cell transplantation, chimeric antigen receptor T cell therapy and immune checkpoint inhibitors. While each of these approaches can be successful, they also fail in many patients as a result of tumour adaptations or diminished function of immune cells. Enhanced immunity can also lead to immune-related adverse events due to on- or off-target effects. We are exploring the mechanisms that underpin these failures and using this information to devise new strategies that can be translated into early phase clinical trials.

Davis Group - Therapeutic opportunities emerging from studies of immune checkpoints

Chapman Group - Genome Diversification in Cancer and Adaptive Immunity

Milne Group - Epigenetics and Gene Regulation in Leukaemia

Hughes Group - Gene Regulation and Human Disease

Davies Group – Genomics and Genome Editing

My lab is interested in understanding how the genome functions and leveraging this to develop genome editing strategies to treat human disease.

Christodoulides Group– Deciphering the role of white and brown adipocytes in metabolic disease.

Patel Group - Origins of Genotoxic metabolism and the DNA damage response in stem and cancer cells

Our work has shown that metabolism both generalized and intrinsic to blood stem cells unleashes reactive metabolites such as the aldehydes – formaldehyde and acetaldehyde.

Hess Group - Ultrahigh field MRI (7T), Cardiac and respiratory motion tracking and correction